AC Immune

Join us at the Symposium on Parkinson’s disease and related disorders! This event will bring together patients and experts from a variety of institutions and associations to share the latest advances in fundamental research, clinical applications and patient care. When: October 25, 2024 Where: EPFL, Building SG, Lausanne Time: 8:30 AM - 4:30 PM Whether you're a patient, caregiver, researcher or healthcare professional, register online by October 20 to connect and collaborate on Parkinson’s research. #Parkinsons #Research #Healthcare #PatientCare #EPFL #PrecisionMedicine

Each October, we mark #DownSyndromeAwarenessMonth – an opportunity to raise awareness of challenges faced by people with #DownSyndrome (DS). It’s important to recognize that people with DS are not only capable of participating in research, but also want to be included. AC Immune is one of the few companies to include people with DS in trials of #Alzheimer’s disease (AD) therapies. This is particularly important because people with DS often get AD when they get older, but they are rarely taken into consideration in clinical development of new therapies – as our CEO Andrea Pfeifer and Michael S. Rafii, MD, PhD recently outlined in an article in Clinical Leader magazine. Our ABATE study is testing an active immunotherapy candidate, ACI-24.060, that teaches the body’s immune system to target pathogenic forms of the beta amyloid protein in the brain, which could potentially delay or prevent the onset of AD. Our experience shows that with advice and support from patients, advocacy groups, caregivers, and KOLs, it is absolutely possible to design studies that are adapted to the unique needs of individuals with DS. Click here for the full article in Clinical Leader https://lnkd.in/ecF3rQqv And here for more on the ABATE Study https://lnkd.in/eudF-VpA #PrecisionMedicine #Neuroscience #Neurodegeneration

By the end of this year, Swissmedic is expected to take a decision on lecanemab, a promising anti-Abeta #Alzheimer’s drug that could bring hope to patients in Switzerland. As Jessica Davis Pluess highlights in her recent SWI swissinfo.ch article, this decision could significantly impact the future of Alzheimer's research. Our CEO Andrea Pfeifer stresses: “Every study improves our understanding of the disease. Based on these successes, the next generation will arrive even faster and provide greater benefits and improved safety.” AC Immune remains at the forefront of AD research and the goal to deliver precision #prevention, with three next-generation active #immunotherapies in clinical trials. Read the full article here: https://lnkd.in/eGNNJKrG #Innovation #Neuroscience #SwissBiotech #LifeSciences

Recruiting individuals with #DownSyndrome (DS) involves special challenges, but we at AC Immune are showing it can be done. As one of the few companies to include people with DS in trials of #Alzheimer's disease (AD) therapies, we are sharing the lessons we have learned in our ABATE Study. Read CEO Andrea Pfeifer and Michael S. Rafii, MD, PhD’s article in Clinical Leader magazine to learn how sponsors can take the steps necessary to ethically fulfill the unmet needs of people with DS enabling them to fully participate in #clinicaltrials for AD.   https://lnkd.in/ecF3rQqv #DSAD

Today, on World Alzheimer's Day, we pause to reflect on the millions affected by this terrible disease worldwide. The growing incidence of neurodegenerative diseases has a huge social and economic impact, and it is imperative that we address it. That’s why we, at AC Immune, are committed to delivering a future where Alzheimer’s disease is diagnosed early and precisely, treated effectively and ultimately prevented. We renew our call on the scientific community, policymakers, and society to join forces in raising awareness and accelerating the development of effective solutions. By working together, we can deliver solutions that could transform the lives of millions of patients and their families and caregivers. Find out more about #WorldAlzheimersDay here https://lnkd.in/ehYfkVGG #PrecisionMedicine #Alzheimers #Neuroscience #Neurodegeneration 

We are delighted to announce that we will receive the second Re𝜏ain-related milestone payment of CHF 24.6 million under the agreement with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company.   The fact that this payment comes earlier than expected is very gratifying as it is based on the rapid rate of pre-screening in the potentially registrational Re𝜏ain Phase 2b clinical trial in preclinical Alzheimer’s disease.   The Re𝜏ain trial is testing the hypothesis that ACI-35.030 has a disease-modifying effect that can delay or prevent the onset of cognitive impairment in individuals with pre-symptomatic AD through inhibition of seeding and spreading of pathological Tau. https://lnkd.in/emF6SYEE #Alzheimers #activeimmunotherapy #precisionmedicine #prevention

We are proud to share that our collaboration partner Life Molecular Imaging has received Fast Track Designation for our partnered Tau PET-tracer PI-2620 from the U.S. Food and Drug Administration (#FDA) covering Alzheimer’s disease, progressive supranuclear palsy and corticobasal degeneration. Fast Track Designation facilitates the development, and expedites the review process of drugs that address serious conditions and fill unmet medical needs. The next-generation tracer PI-2620 is currently being evaluated in the pivotal ADvance Phase 3 clinical trial in Alzheimer’s disease, and is AC Immune’s third product candidate to receive Fast Track Designation from the FDA. https://lnkd.in/dHsfdCFg #biotech #fasttrack #Alzheimers #Neurodegeneration #precisionmedicine

AC Immune reported Q2 2024 financial results and provided a corporate update. Read the full press release here: Link to full PR on ACI website #financialresults #alzheimers #parkinsons #prevention #precisionmedicine

Congratulations to Life Molecular Imaging on their collaboration with the University of Wisconsin-Madison Alzheimer’s Disease Research Center (ADRC) to support the National Institute on Aging (NIA)-sponsored CLARiTI study! We are proud to see our #Tau-#PET tracer PI-2620 contributing to this large consortium #Alzheimer's clinical trial. #precisionmedicine #diagnostics #prevention

Today, at the AAIC 2024 conference, Dr. Madiha Derouazi, CSO of AC Immune, presented data from our novel therapeutic morADC – Morphomer® Antibody Drug Conjugate - for the first time. This powerful new technology synergistically combines AC Immune’s industry-leading SupraAntigen® (biologics) and Morphomer® (small molecule) platforms. morADC are designed for CNS applications and enable single or dual-targeting strategies (e.g. an anti-Abeta antibody combined with an anti-Tau small molecule) to deliver combination therapy in a single therapeutic agent. In addition, conjugation of brain-penetrant Morphomers with a monoclonal antibody can multiply antibody brain exposure. Find out more about this groundbreaking progress in our mission to pioneer precision medicine for neurodegenerative diseases: https://lnkd.in/eThpD5KD #alzheimers #prevention #PrecisionMedicine #AAIC24